Cardiac myosin activation in the treatment of congestive heart failure: New therapeutic options and review of literature
Congestive heart failure (HF) remains a major cause of cardiac-related morbidity and mortality, despite major therapeutic advancements. A newer class of medications has recently been developed which targets the root cause of HF, which is reduced myocardial contractility. This article aims to highlig...
Main Authors: | Arroj Ali, Ramy Abdelmaseih, Ravi Thakker, Mohammed Faluk, Syed Mustajab Hasan |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2021-01-01
|
Series: | Heart Views |
Subjects: | |
Online Access: | http://www.heartviews.org/article.asp?issn=1995-705X;year=2021;volume=22;issue=4;spage=275;epage=279;aulast=Ali |
Similar Items
-
Cardiac myosin activators for heart failure therapy: focus on omecamtiv mecarbil
by: Edgardo Kaplinsky, et al.
Published: (2018-04-01) -
Omecamtiv Mecarbil in the treatment of heart failure: the past, the present, and the future
by: Shujing Zhou, et al.
Published: (2024-03-01) -
Myosin with hypertrophic cardiac mutation R712L has a decreased working stroke which is rescued by omecamtiv mecarbil
by: Aaron Snoberger, et al.
Published: (2021-02-01) -
The myosin activator omecamtiv mecarbil improves wall stress in a rat model of chronic aortic regurgitation
by: Bachar El Oumeiri, et al.
Published: (2021-08-01) -
Omecamtiv mecarbil in precision-cut living heart failure slices: A story of a double-edged sword
by: Jorik H. Amesz, et al.
Published: (2023-09-01)